The bankruptcy underscores the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.

The former Silicon Valley startup co-founded by Anne Wojcicki has been negotiating with potential buyers trying to land a ...

GlaxoSmithKline also made a $300 million equity investment in 23andMe. When 23andMe went public ... if it shows that they have or are at high risk of developing a genetic disease or disorder.

April 22 (Reuters) - Bankrupt genetic test company 23andMe ... Investment in the United States (CFIUS), an interagency body that vets foreign investments into U.S. companies for national security ...

Genetic testing company 23andMe is seeking a new owner as part ... noted that data collected by the company has "always been at risk." The company filed for Chapter 11 in the U.S. Bankruptcy ...

But since 23andMe is not a medical provider it does not have to abide by standard privacy policies that must be followed at a doctor's office. Such services are "not regulated well," said Ayday.

Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.

Competitors like AncestryDNA and MyHeritage, both vying for customers in the at-home genetics and health space ... used by 23andMe, drawn from customer at-home testing kits, poses risks of ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...